1. Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage. (14th October 2021) Authors: Kolkhof, P; Hartmann, E; Freyberger, A; Pavkovic, M; Mathar, I; Sandner, P; Droebner, K; Joseph, A; Eitner, F; Hueser, J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P134Increased beta-adrenergic inotropy in ventricular myocardium from Trpm4 knockout mice. (15th July 2014) Authors: Kecskes, M; Mathar, I; Griet, J; Van Der Mieren, G; Voets, T; Herijgers, P; Vennekens, R Journal: Cardiovascular research Issue: Volume 103(2014)Supplement 1 Page Start: S23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗